Drug firm Lupin on Tuesday said it has received approval from the US health regulator to market its generic Divalproex Sodium extended-release tablets in the American market.
The company has received approval from the United States Food and Drug Administration (USFDA) for its Divalproex Sodium extended-release tablets in the strengths of 250 mg and 500 mg, Lupin said in a statement.
The company's product is a generic version of AbbVie Inc's Depakote extended-release tablets in the same strengths, it added.
As per IQVIA MAT June 2019 data, Divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mg had annual sales of approximately USD 159 million (over Rs 1,100 crore) in the US, Lupin said.
